Lipid parameters and venous thromboembolism: clinical evidence, pathophysiology and therapeutic implications

References

• Sorensen HT, Horvath-Puho E, Sogaard KK etal. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a populationbased case–control study. J.Thromb.Haemost. 7(4), 521–528 (2009).
   Google Scholar
• Prandoni P, Bilora F, Marchiori A etal. An association between atherosclerosis and venous thrombosis. N.Engl.J.Med. 348(15), 1435–1441 (2003).
   Google Scholar
• Hong C, Zhu F, Du D, Pilgram TK, Sicard GA, Bae KT. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 183(1), 169–174 (2005).
   Google Scholar
• Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370(9601), 1773–1779 (2007).
   Google Scholar
• Becattini C, Agnelli G, Prandoni P etal. A prospective study on cardiovascular events after acute pulmonary embolism. Eur.Heart J.26(1), 77–83 (2005).
   Google Scholar
• Prandoni P, Ghirarduzzi A, Prins MH etal. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J.Thromb.Haemost. 4(9), 1891–1896 (2006).
   Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM etal. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 125(1), e2–e220 (2012).
   Google Scholar
• Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBO study group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb.Haemost. 83(5), 657–660 (2000).
   Google Scholar
• Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-ana lysis. Circulation 117(1), 93–102 (2008). ▪▪ Meta-analysis of the risk of venous thromboembolism associated with cardiovascular risk factors.
   Google Scholar
• Frederiksen J, Juul K, Grande P etal. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and Case–control studies from the Copenhagen City Heart Study. Blood 104(10), 3046–3051 (2004).
   Google Scholar
• Kawasaki T, Kambayashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deepvein thrombosis. Thromb.Res. 88(1), 67–73 (1997).
   Google Scholar
• McColl MD, Sattar N, Ellison J etal. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. BloodCoagul.Fibrinolysis 11(3), 225–229 (2000).
   Google Scholar
• Seguí R, Estellés A, Mira Y etal. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br.J. Haematol. 111(1), 122–128 (2000).
   Google Scholar
• Zamani A, Omrani GR, Lankarani KB. Hyperhomocysteinaemia, hyperlipidaemia and risk of venous thromboembolism in Shiraz. EastMediterr.HealthJ.9(5–6), 935–943 (2003).
   Google Scholar
• Vaya A, Mira Y, Ferrando F etal. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br.J.Haematol. 118(1), 255–259 (2002).
   Google Scholar
• Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch.Intern.Med. 162(10), 1182–1189 (2002).
   Google Scholar
• Everett BM, Glynn RJ, Buring JE, Ridker PM. Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women. J.Thromb.Haemost. 7(4), 588–596 (2009).
   Google Scholar
• Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler.Thromb.Vasc.Biol. 24(10), 1970–1975 (2004).
   Google Scholar
• Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 112(6), 893–899 (2005).
   Google Scholar
• Delluc A, Malécot JM, Kerspern H etal. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism. Atherosclerosis 220(1), 184–188 (2012).
   Google Scholar
• Ay C, Tengler T, Vormittag R etal. Venous thromboembolism – a manifestation of the metabolic syndrome. Haematologica 92(3), 374–380 (2007).
   Google Scholar
• Lippi G, Brocco G, Manzato F, Guidi G. Relationship between venous thromboembolism and lipid or lipoprotein disorders. Thromb.Res. 95(6), 353–354 (1999).
   Google Scholar
• Gonzalez-Ordonez AJ, Fernandez-Carreira JM, Fernandez-Alvarez CR etal. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica 88(9), 1035–1043 (2003).
   Google Scholar
• Ageno W, Prandoni P, Romualdi E etal. The metabolic syndrome and the risk of venous thrombosis: a case–control study. J.Thromb.Haemost. 4(9), 1914–1918 (2006).
   Google Scholar
• Steffen LM, Cushman M, Peacock JM etal. Metabolic syndrome and risk of venous thromboembolism: longitudinal investigation of thromboembolism etiology. J.Thromb. Haemost. 7(5), 746–751 (2009).
   Google Scholar
• Doggen CJ, Lemaitre RN, Smith NL, Heckbert SR, Psaty BM. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J.Thromb. Haemost. 2(5), 700–701 (2004).
   Google Scholar
• Chamberlain AM, Folsom AR, Heckbert SR, Rosamond WD, Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 112(7), 2675–2680 (2008).
   Google Scholar
• Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 140(2), 271–280 (1998). ▪▪ Review of the effects of lipid parameters on hemostasis.
   Google Scholar
• Brunzell JD, Davidson M, Furberg CD etal. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J.Am.Coll.Cardiol. 51(15), 1512–1524 (2008).
   Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA etal. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 104(10), 1108–1113 (2001).
   Google Scholar
• Sniderman AD, Furberg CD, Keech A etal. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361(9359), 777–780 (2003).
   Google Scholar
• Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J.Intern.Med. 259(5), 493–519 (2006).
   Google Scholar
• Marcucci R, Liotta AA, Cellai AP etal. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am.J.Med. 115(8), 601–605 (2003).
   Google Scholar
• von Depka M, Nowak-Göttl U, Eisert R etal. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96(10), 3364–3368 (2000).
   Google Scholar
• Császár A, Karádi I, Juhász E, Romics L. High lipoprotein(a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism. Eur.J. Clin.Invest. 25(5), 368–370 (1995).
   Google Scholar
• Rodger MA, Le Gal G, Carrier M etal. Serum lipoprotein (a) levels in patients with first unprovoked venous thromboembolism is not associated with subsequent risk of recurrent VTE. Thromb.Res. 126(3), 222–226 (2010).
   Google Scholar
• Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am.J.Med. 120(8), 728–733 (2007).
   Google Scholar
• Eichinger S, Pecheniuk NM, Hron G etal. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 115(12), 1609–1614 (2007).
   Google Scholar
• Allford S. Haemostasis. Medicine 32(5), 11–14 (2004). ▪▪ Current knowledge of the physiology of hemostasis.
   Google Scholar
• Norris LA. Blood coagulation. BestPract.Res. Clin.Obstet.Gynaecol. 17(3), 369–383 (2003). ▪▪ Current knowledge of the physiology of hemostasis.
   Google Scholar
• Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am.J. Pathol. 138(3), 601–607 (1991).
   Google Scholar
• Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler.Thromb.Vasc. Biol. 17(2), 265–272 (1997).
   Google Scholar
• Carson SD. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBSLett. 132(1), 37–40 (1981).
   Google Scholar
• Lowe GD, Wood DA, Douglas JT etal. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb.Haemost. 65(4), 339–343 (1991).
   Google Scholar
• Hoffman CJ, Lawson WE, Miller RH, Hultin MB. Correlation of vitamin K-dependent clotting factors with cholesterol and triglycerides in healthy young adults. Arterioscler.Thromb. 14(11), 1737–1740 (1994).
   Google Scholar
• Mitropoulos KA, Miller GJ, Reeves BE, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 76(2–3), 203–208 (1989).
   Google Scholar
• Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population – II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb. Haemost. 54(3), 721–723 (1985).
   Google Scholar
• Hoffman CJ, Miller RH, Lawson WE, Hultin MB. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J.Am.Coll.Cardiol. 14(4), 941–946 (1989).
   Google Scholar
• Halle M, Berg A, Keul J, Baumstark MW. Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler. Thromb.Vasc.Biol. 16(1), 144–148 (1996).
   Google Scholar
• Miller GJ, Martin JC, Webster J etal. Association between dietary fat intake and plasma factor VII coagulant activity – a predictor of cardiovascular mortality. Atherosclerosis 60(3), 269–277 (1986).
   Google Scholar
• Saenko EL, Shima M, Sarafanov AG. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex. TrendsCardiovasc.Med. 9(7), 185–192 (1999).
   Google Scholar
• Kjalke M, Silveira A, Hamsten A, Hedner U, Ezban M. Plasma lipoproteins enhance tissue factor-independent factor VII activation. Arterioscler.Thromb.Vasc.Biol. 20(7), 1835–1841 (2000).
   Google Scholar
• Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb.Res. 82(3), 235–244 (1996).
   Google Scholar
• Mariani G, Bernardi F, Bertina R etal. Serum phospholipids are the main environmental determinants of activated factor VII in the most common FVII genotype. European Union Concerted Action “Clotart”. Haematologica 84(7), 620–626 (1999).
   Google Scholar
• Mariani G, Conard J, Bernardi F etal. Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated factor VII. Arterioscler.Thromb.Vasc. Biol. 19(8), 2024–2028 (1999).
   Google Scholar
• Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb.Haemost. 86(1), 386–394 (2001). ▪▪ Reviews the effects of lipid parameters on hemostasis.
   Google Scholar
• Woodward M, Lowe GD, Rumley A etal. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br.J.Haematol. 97(4), 785–797 (1997).
   Google Scholar
• Bradley WA, Gianturco SH. Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin.Thromb. Hemost. 14(3), 253–257 (1988).
   Google Scholar
• de Sousa JC, Soria C, Ayrault-Jarrier M etal. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J.Clin.Pathol. 41(9), 940–944 (1988).
   Google Scholar
• Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler.Thromb. 14(1), 60–69 (1994).
   Google Scholar
• Moyer MP, Tracy RP, Tracy PB, van’t Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler.Thromb.Vasc.Biol. 18(3), 458–465 (1998).
   Google Scholar
• Rota S, McWilliam NA, Baglin TP, Byrne CD. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood 91(2), 508–515 (1998).
   Google Scholar
• Xu N, Dahlbäck B, Ohlin AK, Nilsson A. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler.Thromb.Vasc.Biol. 18(1), 33–39 (1998).
   Google Scholar
• Xu N, Ohlin AK, Zhou L, Nilsson A. Binding of prothrombin to chyle chylomicrons: effects of temperature and calcium ions, and role of surface phospholipids. Thromb.Res. 80(1), 35–46 (1995).
   Google Scholar
• Lowe GD, Drummond MM, Third JL etal. Increased plasma fibrinogen and plateletaggregates in type II hyperlipoproteinaemia. Thromb.Haemost. 42(5), 1503–1507 (1980).
   Google Scholar
• DiMinno G, Silver MJ, Cerbone AM, Rainone A, Postiglione A, Mancini M. Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis 6(2), 203–211 (1986).
   Google Scholar
• Cremer P, Nagel D, Labrot B etal. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur.J.Clin. Invest. 24(7), 444–453 (1994).
   Google Scholar
• Koenig W, Sund M, Ernst E, Mraz W, Hombach V, Keil U. Association between rheology and components of lipoproteins in human blood. Results from the MONICA project. Circulation 85(6), 2197–2204 (1992).
   Google Scholar
• Welty FK, Mittleman MA, Wilson PW etal. Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. Circulation 95(4), 825–830 (1997).
   Google Scholar
• Møller L, Kristensen TS. Plasma fibrinogen and ischemic heart disease risk factors. Arterioscler. Thromb. 11(2), 344–350 (1991).
   Google Scholar
• Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J.Clin.Invest. 103(2), 219–227 (1999).
   Google Scholar
• Lesnik P, Vonica A, Guérin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler. Thromb. 13(7), 1066–1075 (1993).
   Google Scholar
• Zitoun D, Bara L, Basdevant A, Samama MM. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler.Thromb.Vasc.Biol. 16(1), 77–81 (1996).
   Google Scholar
• Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutarylcoenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler.Thromb. 11(1), 138–145 (1991).
   Google Scholar
• Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordøy A. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler.Thromb. 14(2), 223–229 (1994).
   Google Scholar
• Moor E, Hamsten A, Karpe F, Båvenholm P, Blombäck M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb.Haemost. 71(6), 707–712 (1994).
   Google Scholar
• Bertina RM, Koeleman BP, Koster T etal. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475), 64–67 (1994).
   Google Scholar
• Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 343(8909), 1361–1362 (1994).
   Google Scholar
• Voorberg J, Roelse J, Koopman R etal. Association of idiopathic venous thromboembolism with single point-mutation 85 at Arg506 of factor V. Lancet 343(8912), 1535–1536 (1994).
   Google Scholar
• Woodward M, Lowe GD, Rumley A etal. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br.J.Haematol. 97(4), 785–797 (1997).
   Google Scholar
• Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N.Engl. J.Med. 313(25), 1557–1563 (1985).
   Google Scholar
• Levin EG, Miles LA, Fless GM etal. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler.Thromb. 14(3), 438–442 (1994).
   Google Scholar
• Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94(9), 2057–2063 (1996).
   Google Scholar
• Mussoni L, Mannucci L, Sirtori M etal. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler.Thromb. 12(1), 19–27 (1992).
   Google Scholar
• Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10(6), 1067–1073 (1990).
   Google Scholar
• Sironi L, Mussoni L, Prati L etal. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler.Thromb.Vasc.Biol. 16(1), 89–96 (1996).
   Google Scholar
• Tremoli E, Camera M, Maderna P etal. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler. Thromb. 13(3), 338–346 (1993).
   Google Scholar
• Grady D, Wenger NK, Herrington D etal. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann.Intern.Med. 132(9), 689–696 (2000).
   Google Scholar
• Glynn RJ, Danielson E, Fonseca FA etal. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N.Engl.J.Med. 360(18), 1851–1861 (2009). ▪▪ The JUPTER trial: a randomized trial of rosuvastatin in the prevention of venous thromboembolism.
   Google Scholar
• Squizzato A, Galli M, Romualdi E etal. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur. HeartJ.31(10), 1248–1256 (2010). ▪▪ Meta-analysis of lipid-lowering drugs use and the risk of venous thromboembolism.
   Google Scholar
• Agarwal V, Phung OJ, Tongbram V, Bhardwaj A, Coleman CI. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int.J.Clin.Pract. 64(10), 1375–1383 (2010). ▪▪ Meta-analysis of statin use and the risk of venous thromboembolism.
   Google Scholar
• Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler. Thromb.Vasc.Biol. 25(2), 287–294 (2005).
   Google Scholar
• Tsai AW, Cushman M, Rosamond WD etal. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am.J. Med. 113(8), 636–642 (2002).
   Google Scholar
• Eichinger S, Minar E, Bialonczyk C etal. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 290(8), 1071–1074 (2003).
   Google Scholar
• Palareti G, Legnani C, Cosmi B etal. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 108(3), 313–318 (2003).
   Google Scholar
• Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J.Thromb. Haemost. 4(9), 1925–1927 (2006).
   Google Scholar
• Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int. J.Clin.Pract. 60(4), 442–449 (2006).
   Google Scholar
• Keech A, Simes RJ, Barter P etal. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849–1861 (2005).
   Google Scholar
• The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231(4), 360–381 (1975).
   Google Scholar
• Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J.Thromb.Haemost. 3(2), 292–299 (2005).
   Google Scholar
• de Lorgeril M, Salen P, Paillard F, Lacan P, Richard G. Lipid-lowering drugs and homocysteine. Lancet 353(9148), 209–210 (1999).
   Google Scholar
• Giral P, Bruckert E, Jacob N, Chapman MJ, Foglietti MJ, Turpin G. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 154(2), 421–427 (2001).
   Google Scholar
• Lacut K, Le Gal G, Abalain JH, Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates and venous thromboembolism: role of drug induced homocysteinemia? Thromb.Res. 122(3), 314–319 (2008).
   Google Scholar
• Wilkes HC, Meade TW, Barzegar S etal. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb.Haemost. 67(5), 503–506 (1992).
   Google Scholar
• Bröijersén A, Hamsten A, Silveira A etal. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thromb.Haemost. 76(2), 171–176 (1996).
   Google Scholar
• Undas A, Celinska-Löwenhoff M, Domagala TB etal. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb.Haemost. 94(1), 193–199 (2005).
   Google Scholar
• Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch.Intern.Med. 161(11), 1405–1410 (2001).
   Google Scholar
• Herrington DM, Vittinghoff E, Lin F etal. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 105(25), 2962–2967 (2002).
   Google Scholar
• Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br.J. Clin.Pharmacol. 67(1), 99–109 (2009).
   Google Scholar
• Yang CC, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. Br.J. Clin.Pharmacol. 53(1), 101–105 (2002).
   Google Scholar
• Freeman DJ, Robertson M, Brown EA etal. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMCGeriatr. 11, 8 (2011).
   Google Scholar
• Yang CC, Kao CC. Cardiovascular diseases and the risk of venous thromboembolism: a hospital-based case–control study. J.Chin. Med.Assoc. 70(3), 103–109 (2007).
   Google Scholar
• Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch. Intern.Med. 167(9), 935–943 (2007).
   Google Scholar
• Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J.Thromb.Haemost. 7(4), 514–520 (2009).
   Google Scholar